Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study

James W. Mandell, Phosphorylation State-Specific Antibodies : Applications in Investigative and Diagnostic Pathology American Journal of Pathology. ,vol. 163, pp. 1687- 1698 ,(2003) , 10.1016/S0002-9440(10)63525-0

B Sonnweber, High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC) Journal of Clinical Pathology. ,vol. 59, pp. 255- 259 ,(2006) , 10.1136/JCP.2005.027615

Jian-Min Tang, Quan-Ying He, Rui-Xia Guo, Xiu-Jun Chang, Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis Lung Cancer. ,vol. 51, pp. 181- 191 ,(2006) , 10.1016/J.LUNGCAN.2005.10.003

Renee Bailey, Mark Kris, Michael Wolf, Andrea Kay, Steven Averbuch, Jon Askaa, Mette Janas, Karsten Schmidt, Masahiro Fukuoka, O-242 Gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone Lung Cancer. ,vol. 41, ,(2003) , 10.1016/S0169-5002(03)91900-3

Fred R. Hirsch, Giorgio V. Scagliotti, Corey J. Langer, Marileila Varella-Garcia, Wilbur A. Franklin, Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer. ,vol. 41, pp. 29- 42 ,(2003) , 10.1016/S0169-5002(03)00137-5

Odile David, James Jett, Helena LeBeau, Grace Dy, Janet Hughes, Mitchell Friedman, Arnold R. Brody, Phospho-Akt Overexpression in Non–Small Cell Lung Cancer Confers Significant Stage-Independent Survival Disadvantage Clinical Cancer Research. ,vol. 10, pp. 6865- 6871 ,(2004) , 10.1158/1078-0432.CCR-04-0174

Edward S Kim, Vera Hirsh, Tony Mok, Mark A Socinski, Radj Gervais, Yi-Long Wu, Long-Yun Li, Claire L Watkins, Mark V Sellers, Elizabeth S Lowe, Yan Sun, Mei-Lin Liao, Kell Østerlind, Martin Reck, Alison A Armour, Frances A Shepherd, Scott M Lippman, Jean-Yves Douillard, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial The Lancet. ,vol. 372, pp. 1809- 1818 ,(2008) , 10.1016/S0140-6736(08)61758-4

Melania Pintilie, Fiona H. Blackhall, Frances A. Shepherd, Ronald Feld, Natasha Leighl, Ming Sound Tsao, Michael Michael, Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clinical Cancer Research. ,vol. 9, pp. 2241- 2247 ,(2003)

Bret Wacker, Tina Nagrani, Jacqueline Weinberg, Karsten Witt, Gary Clark, Pablo J. Cagnoni, Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies Clinical Cancer Research. ,vol. 13, pp. 3913- 3921 ,(2007) , 10.1158/1078-0432.CCR-06-2610

Jose R. Pereira, Filippo De Marinis, Joachim von Pawel, Ulrich Gatzemeier, Thomas Chang Yao Tsao, Miklos Pless, Thomas Muller, Hong-Liang Lim, Christopher Desch, Klara Szondy, Radj Gervais, Shaharyar, Christian Manegold, Sofia Paul, Paolo Paoletti, Lawrence Einhorn, Paul A. Bunn, Nasser Hanna, Frances A. Shepherd, Frank V. Fossella, Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy Journal of Clinical Oncology. ,vol. 22, pp. 1589- 1597 ,(2004) , 10.1200/JCO.2004.08.163